New hope for transplant patients: immune cell therapy targets stubborn graft-versus-host disease
NCT ID NCT06991361
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether a single dose of specially grown regulatory T cells, combined with daily low-dose interleukin-2, can safely treat chronic graft-versus-host disease (cGvHD) in people whose condition did not improve with steroids or IL-2 alone. About 21 participants aged 2 and older who have had a stem cell transplant will receive the treatment. The main goal is to check for side effects and find a safe dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE (CGVHD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••